Hangzhou Biotest Biotech Co.,Ltd.

SHSE:688767 Stock Report

Market Cap: CN¥3.2b

Hangzhou Biotest BiotechLtd Balance Sheet Health

Financial Health criteria checks 6/6

Hangzhou Biotest BiotechLtd has a total shareholder equity of CN¥2.4B and total debt of CN¥299.0K, which brings its debt-to-equity ratio to 0.01%. Its total assets and total liabilities are CN¥2.5B and CN¥151.0M respectively. Hangzhou Biotest BiotechLtd's EBIT is CN¥45.4M making its interest coverage ratio -0.7. It has cash and short-term investments of CN¥1.6B.

Key information

0.01%

Debt to equity ratio

CN¥299.03k

Debt

Interest coverage ratio-0.7x
CashCN¥1.61b
EquityCN¥2.38b
Total liabilitiesCN¥150.96m
Total assetsCN¥2.53b

Recent financial health updates

No updates

Recent updates

Hangzhou Biotest BiotechLtd's (SHSE:688767) Solid Profits Have Weak Fundamentals

Nov 06
Hangzhou Biotest BiotechLtd's (SHSE:688767) Solid Profits Have Weak Fundamentals

We Think You Can Look Beyond Hangzhou Biotest BiotechLtd's (SHSE:688767) Lackluster Earnings

May 03
We Think You Can Look Beyond Hangzhou Biotest BiotechLtd's (SHSE:688767) Lackluster Earnings

Financial Position Analysis

Short Term Liabilities: 688767's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥140.3M).

Long Term Liabilities: 688767's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥10.7M).


Debt to Equity History and Analysis

Debt Level: 688767 has more cash than its total debt.

Reducing Debt: 688767's debt to equity ratio has reduced from 24.5% to 0.01% over the past 5 years.

Debt Coverage: 688767's debt is well covered by operating cash flow (68190.6%).

Interest Coverage: 688767 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies